Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...

Sanofi has won US Food and Drug Administration (FDA) approval for haemophilia treatment Qfitlia (fitusiran), as the company ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat ...

Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the ...

FDA approves Sanofi's Qfitlia for hemophilia A & B, reducing bleeding rates. Learn about its benefits, risks, and market ...